New NHS-Galleri study results show that the trial did not meet its primary endpoint of a statistically significant reduction in combined Stage III and IV cancer diagnoses. Secondary findings were more encouraging, although they should be interpreted cautiously. For i...
In this Q&A originally published in the program for the inaugural Life-Re Europe conference, RGA leaders Jonathan Porter and Cormac Galvin discuss the growth and future of asset-intensive reinsurance in Continental Europe.
RGA monitors global life and health insurance product launches every quarter, across product types, distribution approaches, and value-added services. Find a roadmap for navigating today’s product landscape in Product Trends Around the World.
Read More
RGA Korea CEO Michael Shin tells Asia Insurance Review that while South Korea’s critical illness market is among the world’s most developed, insurers must pivot from price‑driven competition to holistic, longevity‑focused solutions to close protection gaps i...
Read MoreRGA produces a number of specialized publications featuring expert opinion and analysis. Explore our public collection or contact us for whitepapers, webinars, and other resources.
Explore the industry's premier medical underwriting publication.
Explore the ReFlections SeriesInvestigate product development trends and developments from around the world.
Explore the Product Trends Series
